Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18539783 | 0.86 | HPGD (0.45) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL2206291 | 0.86 | HPGD (0.51) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL25817595 | 0.86 | HPGD (0.51) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL25825857 | 0.86 | HPGD (0.46) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL8899070 | 0.85 | KAT6A (0.48) | KAT6ANR1H4SIRT2PARP15PARP10 | |
| SCHEMBL19291614 | 0.84 | NR1H4 (0.49) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL25826152 | 0.81 | SIRT2 (0.44) | HPGDRAB9ASMN1; SMN2KAT6ANR1H4 | |
| SCHEMBL19291642 | 0.78 | HTR1B (0.50) | SMN1; SMN2SIRT2CARM1PRMT6ADAM17 | |
| SCHEMBL25819210 | 0.78 | HTR1B (0.50) | SMN1; SMN2SIRT2CARM1PRMT6ADAM17 | |
| SCHEMBL18721737 | 0.78 | HTR1B (0.50) | SMN1; SMN2SIRT2CARM1PRMT6ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | HPGD 110/4885RAB9A 2078/4885SMN1; SMN2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.